Stryker Corp. | StockChase
44
Stryker Corp. (SYK-N)

Last Price Recorded: $156.4800 on 2017-11-16

ON STOCKCHASE SINCE Feb 2002

manufactures orthopedic equipment

biotechnology/pharmaceutical

Stryker Corp.


Signal Opinion Expert

2017-10-17

BUY on WEAKNESS
Stryker Corp. (SYK-N)

He likes this company. Anything in the S&P 500, or even the S&P 100, is perfect for him. This closed at $147.29. Has a model price of $140, and the stock is just a little ahead of itself. Would be a buyer on any pullback.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $148.790
Owned: Unknown

2017-10-13

HOLD
Stryker Corp. (SYK-N)

Great company. They are improving their return on capital. Have done everything you could possibly want them to do as a company. However, there is a runaway stock price. If you own it, Hold and look for a better exit.

biotechnology/pharmaceutical
Matt Kacur

President, FSA Financial Science and Art

Price: $146.690
Owned: Unknown

2017-09-14

BUY
Stryker Corp. (SYK-N)

Hips, Knees and Ankles.  They are capturing market share.  He is seeing great take up here.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $144.490
Owned: Yes

2017-08-25

COMMENT
Stryker Corp. (SYK-N)

Seasonal strength is from the beginning of June until the middle of July and then goes sideways after that.  We reached the end of the seasonal strength in the sector.  You could hold until the next period of seasonal strength or sell it.

biotechnology/pharmaceutical
Don Vialoux

Research Analyst, TimingTheMarket.CA & EquityClock.COM

Price: $139.880
Owned: Unknown

2017-08-21

TOP PICK
Stryker Corp. (SYK-N)

Comparing them to JNJ-N, SYK-N is blowing them out of the water.  They are doing 3D printers to create products where bone can grow back.  Dividend growth is in the 20% range.  (Analysts’ target: US$156.00).

biotechnology/pharmaceutical
David Driscoll

President & CEO, Liberty International Investment Management Inc

Price: $145.130
Owned: Yes

2017-05-09

COMMENT
Stryker Corp. (SYK-N)

The medical device space has done well in healthcare. This goes back to so much money having left biotech. Part of what drives this one is surgical procedure growth. As the population ages, you need to get more surgical procedures. There are some good trends behind this company and it has been executing well. (See Top Picks.)

biotechnology/pharmaceutical
Jennifer Radman

VP & Sr. Portfolio Manager, Caldwell Investment Management

Price: $134.870
Owned: Unknown

2017-03-16

TOP PICK
Stryker Corp. (SYK-N)

This is known for knees and hips, and they have sold millions of knee replacement implants. They’ve recently started using a robot to replace the body parts, giving greater accuracy and lower costs. With the robot, you can only use their parts, making it a closed system. He doesn’t foresee any changes in the US health care act having an effect on this company and their equipment. Dividend yield of 1.3%. (Analysts’ price target is $132.)

biotechnology/pharmaceutical
Zachary Curry

Chief Operating Officer & Portfolio Manager, Davis-Rea Ltd.

Price: $131.500
Owned: Yes

2017-03-01

BUY
Stryker Corp. (SYK-N)

This is a business that people need to have exposure to. His clients own a similar company, Zimmer Biomet (ZBH-N) which manufactures replacements for hips, knees, and they do stuff for your back, dental. This is a business that unfortunately is going to do well as people age and live longer and wear out their useful parts. Hips and knee replacements is going to grow at a significant rate, and there are only a few companies that manufacture these things.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Management

Price: $131.050
Owned: No

2017-02-27

DON'T BUY
Stryker Corp. (SYK-N)

It is an interesting space, but expensive.  Wait until we get clarity on what is happening with Obamacare.  Investors may migrate out of the devices group.

biotechnology/pharmaceutical
James Thorne

Sr Portfolio Manager & Chief Capital Markets Strat, Caldwell Investment Management

Price: $128.580
Owned: Unknown

2017-02-22

BUY
Stryker Corp. (SYK-N)

This is a long-term Hold. He recently added to his holdings. This is your hip, knees, ankles, feet, prosthetics. You are paying a little bit more for their growth. This is going to be the wave of the future. Feels they are capturing market share.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $127.290
Owned: Yes

2017-01-12

PAST TOP PICK
Stryker Corp. (SYK-N)

(Top Pick Feb 25/16, Up 21.75%) He is not chasing high flying pharma, but the more steady, boring ones that people use more and more as they age.  They grow by acquisition. 

biotechnology/pharmaceutical
Mohsin Bashir

VP Investments, Stone Asset Management

Price: $123.260
Owned: Yes

2016-11-15

DON'T BUY
Stryker Corp. (SYK-N)

When it comes to healthcare stocks, you have to differentiate between those pharmaceuticals that have very good margins without any threat to their profit margins, and a stock like this that makes implants. In the field of implants, there has been very little innovation in the last 10 years, and he thinks problems are going to come from both Medicare and Medicaid. Thinks they are going to be pushing prices down, not up, which is a threat to the implant manufacturers.

biotechnology/pharmaceutical
John Burke

CEO & CIO, Burke Financial Strategies

Price: $109.740
Owned: Unknown

2016-08-31

PAST TOP PICK
Stryker Corp. (SYK-N)

(A Top Pick Feb 25/16. Up 14.39%.) Hospital equipment. The growth drivers are charged by the demographics, but also having really high quality equipment, and making strategic acquisitions to integrate itself into the hospital industry structure in a better way. (Wouldn’t buy at current prices, but wait for a 10% pullback at least.)

biotechnology/pharmaceutical
Mohsin Bashir

VP Investments, Stone Asset Management

Price: $115.660
Owned: Yes

2016-06-21

COMMENT
Stryker Corp. (SYK-N)

Demographically this is really positive. Mr. Trump and Mrs. Clinton debate doesn’t factor into a company like this. They make knees and hips, and are into shoulders a bit now. They now include technology so that if a hip has problems, it can send a message. A little expensive, but a good grower and there is room for acquisitions.

biotechnology/pharmaceutical
Zachary Curry

Chief Operating Officer & Portfolio Manager, Davis-Rea Ltd.

Price: $116.460
Owned: Yes

2016-04-18

BUY
Stryker Corp. (SYK-N)

Thinks this is a probably going to be a good time to be investing in manufacturers of medical devices. There is a whole seasonality that starts in January with a little bit of a pickup in February. They tend to peak every year right around August/September, so there is a bit of time to ride this out.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $110.390
Owned: Unknown

Showing 1 to 15 of 44 entries
<< < 1 2 3 > >>

No Comments.


You must be logged in to comment.